Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-02-19

EMA Authorised: Dovprela (previously Pretomanid FGK) (pretomanid) — Mylan IRE Healthcare Limited

View source ↗

Summary

The European Medicines Agency authorised Dovprela (pretomanid) for tuberculosis, including multidrug-resistant tuberculosis, with orphan medicine designation fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dovprela (pretomanid)

Snippet

Status: Authorised. Therapeutic area: Tuberculosis, Multidrug-Resistant. MAH: Mylan IRE Healthcare Limited. Decision date: 19/01/2026. Orphan medicine